Generex Biotechnology Corporation Announces Interim Results Of Clinical Breast Cancer Trials

Generex Biotechnology Corporation (NASDAQ: GNBT) announced today interim results of an ongoing clinical trial designed to assess the safety and immunological potency of a novel peptide vaccine in patients with breast cancer. The therapeutic vaccine is being developed by its wholly owned subsidiary, Antigen Express.

MORE ON THIS TOPIC